Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years old and above. Clinical selection for Ciclesonide inhaler should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Maximum benefit may not be achieved for 4 weeks or longer after initiation. It is desirable to titrate to the lowest effective dosage to reduce the possibility of side effects.
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Store as labelled. Keep out of reach of children.